Abbott Laboratories
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert Ford
- Full Time Employees
- 114,000
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 100 Abbott Park Road Abbott Park IL United States of America 60064-6400
- IPO Date
- Mar 17, 1980
- CIK
- 0000001800
- Website
- abbott.com
- Similar Companies
- Business
- Abbott Laboratories (NYSE: ABT) develops, manufactures, and sells a broad range of health care products worldwide. The company operates through four main segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices; its core offerings include branded generic pharmaceuticals such as Branded generics in emerging markets, anti-infectives, and gastrointestinal drugs; diagnostics encompassing point-of-care testing systems like i-STAT, molecular diagnostics via Alinity platforms, rapid diagnostics under BinaxNOW and Determine brands, and core laboratory instruments; nutritional products including pediatric formulas like Similac and Pediasure, adult nutritionals such as Ensure and Glucerna, and medical foods; as well as medical devices featuring cardiovascular and neuromodulation devices including FreeStyle Libre continuous glucose monitoring systems, Aveir leadless pacemakers, TactiFlex ablation catheters, and structural heart devices like Amplatzer occluders. Abbott serves health care professionals, consumers, hospitals, laboratories, and governments across more than 100 countries, with principal manufacturing facilities in the United States, Europe, Asia, and Latin America. Founded in 1888 and headquartered in Abbott Park, Illinois, the company maintains a diversified portfolio without notable subsidiaries or parent relationships impacting its core structure. In recent developments within the last two years, Abbott completed the acquisition of Cardiovascular Systems, Inc. in 2024 to expand its cardiovascular portfolio; launched the FreeStyle Libre 3 integrated continuous glucose monitoring sensor in multiple markets including the U.S.; introduced the AVEIR DR dual chamber leadless pacemaker system and the TactiFlex Sensor Enabled Ablation Catheter; formed strategic partnerships for digital health integrations and expanded diagnostics manufacturing capacity amid global demand surges; and reported strong growth in its diabetes and cardiovascular segments during 2025 earnings.
3 Reasons to Buy AbbVie Stock Like There's No Tomorrow
Johnson & Johnson vs Abbott Laboratories: Two Healthcare Giants on Opposite Trajectories
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Andra AP fonden Has $21.22 Million Stock Holdings in Abbott Laboratories $ABT
Abbott Laboratories $ABT Shares Sold by AlTi Global Inc.
Ascent Wealth Partners LLC Reduces Position in Abbott Laboratories $ABT
Assetmark Inc. Boosts Holdings in Abbott Laboratories $ABT
AIA Group Ltd Boosts Holdings in Abbott Laboratories $ABT
Allspring Global Investments Holdings LLC Increases Holdings in Abbott Laboratories $ABT
Abbott: Bear Trap Over, With Richer Return Prospects
Abbott investigates two separate cyber incidents, says no operations affected
ABT Q2 Earnings Call Flags Stronger Second-Half Setup
These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results
Compass Pathways gains Jefferies support as COMP360 data distinguishes psychological support from psychotherapy
Abbott To Rally More Than 35%? Here Are 10 Top Analyst Forecasts For Friday
Abbott Laboratories: Pick Up This Dividend King Deal Now
Abbott Laboratories (NYSE:ABT) Shares Gap Up Following Better-Than-Expected Earnings
Why Abbott Stock Jumped Today
Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
Abbott Laboratories (ABT) Q2 2026 Earnings Call Transcript